Resources for Food and Drug Administration (FDA)

Drug Makers Say FDA Safety Focus Is Slowing New-Medicine Pipeline

online.wsj.com

Nearly four years after Merck & Co. yanked the painkiller Vioxx off the market, beleaguered pharmaceutical-industry executives say they are facing a tough new regulatory climate that is altering the landscape of drug development. Over the past 16 months, Schering-Plough Corp. Chief Executive Fred Hassan and his top scientists have pulled the plug on two drug-development projects -- one for obesity and the other for cholesterol -- that had the potential to produce big sellers. And they're considering scrapping a third.

View the Resource

Share or bookmarklet this web page at: